These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 26320256)

  • 1. CD4+ T Cell Help Selectively Enhances High-Avidity Tumor Antigen-Specific CD8+ T Cells.
    Zhu Z; Cuss SM; Singh V; Gurusamy D; Shoe JL; Leighty R; Bronte V; Hurwitz AA
    J Immunol; 2015 Oct; 195(7):3482-9. PubMed ID: 26320256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism.
    Xu S; Koski GK; Faries M; Bedrosian I; Mick R; Maeurer M; Cheever MA; Cohen PA; Czerniecki BJ
    J Immunol; 2003 Sep; 171(5):2251-61. PubMed ID: 12928369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response.
    Ercolini AM; Ladle BH; Manning EA; Pfannenstiel LW; Armstrong TD; Machiels JP; Bieler JG; Emens LA; Reilly RT; Jaffee EM
    J Exp Med; 2005 May; 201(10):1591-602. PubMed ID: 15883172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy.
    Mittal P; St Rose MC; Wang X; Ryan JM; Wasser JS; Vella AT; Adler AJ
    J Immunol; 2015 Dec; 195(12):5816-26. PubMed ID: 26561553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens.
    Côté AL; Zhang P; O'Sullivan JA; Jacobs VL; Clemis CR; Sakaguchi S; Guevara-Patiño JA; Turk MJ
    J Immunol; 2011 Jan; 186(1):275-83. PubMed ID: 21106849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy.
    Snook AE; Magee MS; Schulz S; Waldman SA
    Eur J Immunol; 2014 Jul; 44(7):1956-66. PubMed ID: 24771148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens.
    Van Nuffel AM; Tuyaerts S; Benteyn D; Wilgenhof S; Corthals J; Heirman C; Neyns B; Thielemans K; Bonehill A
    J Immunol Methods; 2012 Mar; 377(1-2):23-36. PubMed ID: 22269772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential kinetics of antigen dependency of CD4+ and CD8+ T cells.
    Rabenstein H; Behrendt AC; Ellwart JW; Naumann R; Horsch M; Beckers J; Obst R
    J Immunol; 2014 Apr; 192(8):3507-17. PubMed ID: 24639353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of homologous rather than heterologous antigen-specific CD4 T cell responses is critical for functional CD8 T cell responses in mice transgenic for a foreign antigen.
    Sabarth N; Chamberlain L; Brett S; Tite J; Craigen J
    J Immunol; 2010 Oct; 185(8):4590-601. PubMed ID: 20861346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.
    Moore TV; Lyons GE; Brasic N; Roszkowski JJ; Voelkl S; Mackensen A; Kast WM; Le Poole IC; Nishimura MI
    Cancer Immunol Immunother; 2009 May; 58(5):719-28. PubMed ID: 18836717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells.
    Ribas A; Wargo JA; Comin-Anduix B; Sanetti S; Schumacher LY; McLean C; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS
    J Immunol; 2004 Apr; 172(8):4762-9. PubMed ID: 15067052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
    Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
    J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The fate of low affinity tumor-specific CD8+ T cells in tumor-bearing mice.
    Lyman MA; Nugent CT; Marquardt KL; Biggs JA; Pamer EG; Sherman LA
    J Immunol; 2005 Mar; 174(5):2563-72. PubMed ID: 15728462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.
    Ribas A; Butterfield LH; Amarnani SN; Dissette VB; Kim D; Meng WS; Miranda GA; Wang HJ; McBride WH; Glaspy JA; Economou JS
    Cancer Res; 2001 Dec; 61(24):8787-93. PubMed ID: 11751400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses.
    Nouri-Shirazi M; Banchereau J; Bell D; Burkeholder S; Kraus ET; Davoust J; Palucka KA
    J Immunol; 2000 Oct; 165(7):3797-803. PubMed ID: 11034385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
    Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
    Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells.
    Wong SB; Bos R; Sherman LA
    J Immunol; 2008 Mar; 180(5):3122-31. PubMed ID: 18292535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
    Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
    Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor.
    Ghorashian S; Veliça P; Chua I; McNicol AM; Carpenter B; Holler A; Nicholson E; Ahmadi M; Zech M; Xue SA; Uckert W; Morris E; Chakraverty R; Stauss HJ
    J Immunol; 2015 Feb; 194(3):1080-9. PubMed ID: 25539815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor.
    Baxevanis CN; Voutsas IF; Tsitsilonis OE; Gritzapis AD; Sotiriadou R; Papamichail M
    J Immunol; 2000 Apr; 164(7):3902-12. PubMed ID: 10725753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.